Constarium
← Search

Data · dataset · 2026

The identification of novel immune activating agents for rationalised combination therapy in breast cancer

Listed in ZivaHub and Deakin Research Online and DMU Figshare — shown once because both records carry DOI 10.17034/32639610.v1

The DNA damage induced immune response (DDIR) signature was established to identify breast tumours with an intrinsic DNA damage repair defect that renders them susceptible to DNA damaging chemotherapy, anthracyclines and cyclophosphamide.

Description

This signature is characterised by activation of the cGAS/STING mediated innate immune response pathway and results in a classical type I interferon response, in addition it also activates immune checkpoint signalling.

Taken together this suggests that activation of the DDIR may convert immunologically ‘cold’ tumours to ‘hot’ tumours, that may be responsive to immune checkpoint inhibition. This project aims to identify novel immune activating agents which have the potential for rationalised combination therapy with immune checkpoint blockade (ICB) in breast cancer. This project has incorporated two screening protocols, one smaller scale Broad Institute connectivity mapping directed screen utilising RT-qPCR assessment of interferon stimulated gene (ISG) expression.

Read the rest (2 more)

Then a second large sale high throughput screen of the ApexBio DiscoveryProbe FDA-approve compound library utilising an ELISA to detect CCL5 secretion. A total of 11 compounds were taken forward and validated using RNA sequencing to look at immune stimulated gene expression. The chicken chorioallantoic membrane (CAM) model was trialled as a method for assessing the immune activating potential of these compounds in combination with ICB.

In doing this we hope to repurpose approved drugs for immune activation and rationalised combination therapy with ICB in breast cancer. <br><br><i>Thesis embargoed until 31 July 2029.</i>

Links

Where it is published

Catalogue records · 1

Topics

Inferred from text
Cancer 75% · Oncology and carcinogenesis 71% · RNA sequencing 75% · Sequencing 75%
Provenance · 3 source records, 15 field assertions
SourceKeyLast seenRaw
ZivaHuboai:figshare.com:article/3263961011 d agoJSON v1
Deakin Research Onlineoai:figshare.com:article/3263961011 d agoJSON v1
DMU Figshareoai:figshare.com:article/3263961011 d agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[disease].local:disease:cancerenrichment · zivahub uct ac zakeyword-concept-rules@1.0.0title+description (75%)
concepts[field].anzsrc:group:3211enrichment · zivahub uct ac zataxonomy-embedding@1.1.0title+keywords+description (71%)
concepts[field].local:field:earth-environmentalmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
concepts[field].local:field:earth-environmentalmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:earth-environmentalmapping · figshare dmu ac ukconnector:figshare_dmu_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
concepts[field].local:field:medicine-healthmapping · dro deakin edu auconnector:dro_deakin_edu_au@1.0.0
concepts[field].local:field:medicine-healthmapping · figshare dmu ac ukconnector:figshare_dmu_ac_uk@1.0.0
concepts[modality].local:modality:rna-seqenrichment · zivahub uct ac zakeyword-concept-rules@1.0.0title+description (75%)
concepts[modality].local:modality:sequencingenrichment · zivahub uct ac zakeyword-concept-rules@1.0.0title+description (75%)
descriptionsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/description
license_textsource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
publication_datesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0
titlesource · zivahub uct ac zaconnector:zivahub_uct_ac_za@1.0.0/metadata/dc/title